Author(s): Mohammad Hossein Mozafary Bazargany*, Mehdi Sheibani, Hadis(th) Rastad, Jamal Moosavi, Niloofar Gholami and Hamed Talakoob
SARS-CoV-2 may establish a hypercoagulable state and disrupts hemostasis, predisposing patients to thrombotic events.
A 64-year-old man with a history of diabetes, hypertension, and coronary artery bypass surgery presented with lethargy, terminated ventricular tachycardia, and acute left upper limb ischemia (ALI). His ECG demonstrated anterior Acute Myocardial Infarction (AMI).
We diagnosed COVID-19 according to typical chest Computed Tomography (CT) scan findings (peripheral ground-glass opacities) alongside common clinical features and a history of recent contact with coronavirus disease 2019 (COVID-19) patient. His AMI, unlike his ALI, did respond to fibrinolytic therapy.
Thereby, the patient underwent an emergent embolectomy, which saved his limb. He was under COVID-19 treatment and limb physiotherapy for 12 days. He was discharged on day 13 of admission and recovered from AMI, ALI, and COVID-19 with a 25%ejection fraction.
We reported this case to emphasize the extent of thrombotic events in COVID-19 patients and the emergent multi-disciplinary care they may need. Thrombolytic therapy could be an option in prolonged ischemia if advanced interventional equipment is not available.
